An exterior view of Jiangsu Anbison Pharmaceutical. [Photo/Taizhou Medical High-tech Zone via WeChat account weigg6666]
Two medicine products developed by Jiangsu Anbison Pharmaceutical, located in the Taizhou Medical High-tech Zone, Taizhou city, East China's Jiangsu province, were recently approved by the National Medical Products Administration and passed consistency evaluations.
The drug consistency review is a drug quality requirement set by the country, requiring that generic drugs must have the same quality and efficacy as the original drugs.
The two products are the Mesalamine Extended Release Capsules and the Mesalazine Gastro-resistant Prolonged-release Granules.
During the research and development process, the company overcome multiple technical difficulties and established a stable production process.
The quality equivalence and clinical safety equivalence of the self-made products and reference preparations were ensured through systematic pharmaceutical research and quality comparisons.
The company's production lines of solid preparations and sterile preparations are designed and constructed in accordance with the cGMP or Current Good Manufacturing Practice standards.
They are designed with a production capacity of 300 million hard capsules, 500 million tablets, 40 million bags of granules, 20 million suppositories, 2 million bottles of freeze-dried powder injections, 4 million bottles of sterile injections and 50 million eye drops.